- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07332351
Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial (TRIFECTA)
Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)
This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with enfortumab vedotin and pembrolizumab before (neoadjuvant) radical cystectomy in treating patients with muscle invasive bladder cancer. The combination of enfortumab vedotin and pembrolizumab are already considered standard of care in the treatment of muscle invasive bladder cancer. This trial attempts to determine whether the addition of nadofaragene firadenovec to the current standard regiment is safe and can improve oncological outcomes for those with muscle invasive bladder cancer.
Nadofaragene firadenovec, a type of intravesical gene therapy, is a weakened adenovirus that carries a copy of the gene for interferon alfa-2b. This medication gets absorbed by the bladder and stimulates the bladder to naturally create interferon alfa-2b, which is thought to kill bladder cancer. Nadofaragene firadenovec is given in a solution that is placed directly into the bladder (intravesical) using a thin tube called a catheter. It is a medication that is already Food and Drug Administration approved for the treatment of non-muscle invasive bladder cancer.
Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread.
Investigators aim to assess whether adding intravesical nadofaragene firadenovec to the current recommended treatment of enfortumab vedotin and pembrolizumab before undergoing a radical cystectomy may be safe, tolerable, and/or effective in treating patients with muscle-invasive bladder cancer.
Przegląd badań
Status
Warunki
Szczegółowy opis
OUTLINE:
Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin intravenously (IV) on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity. In addition, patients will also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (one total dose during the entire neoadjuvant period). Starting 4-8 weeks after completion of treatment, patients undergo radical cystectomy (RC) per standard clinical care. Additionally, patients undergo urine and blood sample collection and computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT throughout the study.
After completion of study treatment, patients are followed for up to 30 days post-cystectomy to monitor for adverse events.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Jonathan Wright, MD
- Numer telefonu: 206-598-4294
- E-mail: jlwright@uw.edu
Lokalizacje studiów
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
Główny śledczy:
- Jonathan Wright, MD
-
Kontakt:
- Jonathan Wright, MD
- Numer telefonu: 206-598-4294
- E-mail: jlwright@uw.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age ≥ 18 years at the time of screening
- Ability to understand and willingness to sign the written informed consent document
- Patients with confirmed muscle-invasive urothelial carcinoma of the bladder (cT2-4a, N0-1, M0 or cT1, N1, M0), who are planning to undergo RC
- Pure urothelial or mixed histologic subtypes are allowed if urothelial is the primary histology (regardless of the % of conventional urothelial histology; however, any % of small cell/neuroendocrine is excluded)
- Eligible to receive neoadjuvant enfortumab vedotin and pembrolizumab (EV-P) per the patient's medical oncologist's discretion
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Hemoglobin ≥ 9 g/dL
- Absolute neutrophil count of ≥ 1500 cells/uL
- Platelet count of ≥ 100,000/uL
- Alanine and aspartate aminotransferase levels ≤ 2.5 x upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN for Gilbert syndrome)
- Creatinine clearance or estimated glomerular filtration rate (GFR) ≥ 30ml/min (using Chronic Kidney Disease Epidemiology Collaboration Formula [CKD-EPI] 2021 or Cockcroft-Gault equation)
- For patients with evidence of, or history of HIV, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, the viral load must be undetectable, or the infection must have been treated and cured. Patients are not allowed to be on therapy agents given for HIV, HBV or HCV. Routine testing for HIV, HBV and HCV is not required for patients without such history unless clinically indicated
- Individuals with prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll
Exclusion Criteria:
- cT4b, N2-3, or M1 clinical stage at time of screening
- Any known concurrent clinically relevant malignancies (discussion with trial principal investigator [PI] can be considered)
- Prior systemic therapy for MIBC or non-muscle invasive bladder carcinoma (NMIBC)
- Current or prior use of systemic immunosuppressive medication within 14 days before first dose of investigational product. The following are allowed (not systemic route): intranasal, inhaled, intra-auricular, intra-articular, topical steroids, local steroid injections
- Pure non-urothelial histology subtype/variant or any neuroendocrine (small or large cell) component
- Prior treatment with adenovirus-based drugs
- Known hypersensitivity or allergy to any components of rAd-interferon (IFN)a/Syn3
- Currently receiving other investigational agent
- Pregnant or lactating women
- Inability to comprehend and provide informed consent
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treatment
Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin IV on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. In addition, patients also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (total of 1 dose in neoadjuvant period). Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Starting 4-8 weeks after treatment, patients undergo RC per standard clinical care. Additionally, patients undergo urine and blood sample collection and CT, MRI or PET/CT throughout the study. |
Undergo MRI
Inne nazwy:
Given IV
Inne nazwy:
Undergo CT or PET/CT
Inne nazwy:
Undergo PET/CT
Inne nazwy:
Given IV
Inne nazwy:
Undergo urine and blood sample collection
Inne nazwy:
Given intravesically
Inne nazwy:
Undergo RC
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of patients who receive nadofaragene firadenovec and complete at least 2 cycles of enfortumab vedotin and pembrolizumab in the neoadjuvant period followed by radical cystectomy
Ramy czasowe: Within 10 weeks from last neoadjuvant therapy dose
|
Will be calculated as the number of patients who complete the planned course divided by the total number of enrolled patients who initiate therapy. Exact 95% confidence intervals will be reported. Reasons for non-completion will be summarized descriptively. |
Within 10 weeks from last neoadjuvant therapy dose
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of grade 3 or higher treatment-related adverse events (AE)
Ramy czasowe: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
Will be graded by provider-scored toxicity via the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Will be summarized descriptively, including the number and proportion of patients experiencing at least one grade ≥ 3 AE, and the type, severity, and relatedness of all treatment-related AEs, attributed by agent. |
From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
|
Incidence of AEs
Ramy czasowe: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
Will be summarized by maximum CTCAE grade and relatedness to the treatment. |
From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
|
|
Pathologic complete response (pCR) on radical cystectomy (RC) specimen
Ramy czasowe: At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
Will be defined as the proportion of participants achieving ypT0N0. Will assume the null hypothesis that the true pCR rate is 56 % with the alternative hypothesis of 65%. The observed pCR rate will be reported with an exact 95% confidence interval using the Clopper-Pearson method. |
At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
|
Downstaging (≤ ypT1N0) on RC specimen
Ramy czasowe: At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Jonathan Wright, MD, Fred Hutch/University of Washington Cancer Consortium
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Nowotwory urologiczne
- Choroby Pęcherza Moczowego
- Nowotwory pęcherza moczowego
- Aminokwasy, peptydy i białka
- Białka tkanek nerwowych
- Białka
- Techniki śledcze
- Procedury chirurgiczne, operacyjny
- Techniki chemii, analityczne
- Analiza widma
- Urologiczne procedury chirurgiczne
- Procedury chirurgiczne moczowo -płciowe
- Fosfoproteiny
- pembrolizumab
- Spektroskopia rezonansu magnetycznego
- enfortumab vedotyna
- Wycięcie pęcherza
- Synapsyny
Inne numery identyfikacyjne badania
- RG1126027
- NCI-2025-09407 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .